Pharma supply chains face critical shortages and price pressures in early 2026
The start of 2026 brings fresh challenges for pharmaceutical supply chains across Germany and beyond. With nearly 550 medications already listed as unavailable by the Federal Institute for Drugs and Medical Devices (BfArM), businesses must act swiftly to secure stocks and manage costs. January has become a critical month for setting priorities, finalising contracts, and preparing for seasonal demands like the upcoming flu season.
In Germany, the Paul-Ehrlich-Institut (PEI) is coordinating vaccine stockpiles for 2026, working alongside manufacturers such as BioNTech, CureVac, GSK, and Sanofi. The Robert Koch Institute (RKI) supports epidemiological planning, while the Federal Ministry of Health (BMG) ensures alignment with producers. Orders for flu vaccines, due by late January, will shape preparations starting in mid-February or March.
At the EU level, the European Commission and the European Medicines Agency (EMA) are managing centralised procurement through the HERA mechanism. Key suppliers like Pfizer-BioNTech, Moderna, and Novavax are involved in this effort. Globally, the World Health Organization (WHO) guides recommendations via its Strategic Advisory Group of Experts (SAGE), with COVAX and AstraZeneca playing major roles in distribution. Back offices face a tight schedule in January. They must verify shipment confirmations for contracts finalised in December, check warehouse capacity, and update pricing terms. Companies adjusting prices in 2026 need to track remaining stock at old rates or recalculate selling prices immediately. Close collaboration with field sales teams is also essential to secure priority allocations if rationing occurs due to shortages or logistical delays. Proactive inventory planning remains vital to cushion the impact of price hikes and supply chain disruptions. Reviewing post-stockpiling adjustments, annual agreements, and return policies will help maintain stability for the year ahead.
The first quarter of 2026 will test the resilience of pharmaceutical supply chains. Businesses that verify contracts, align with suppliers, and prepare for seasonal demands early will be better positioned to handle shortages and price changes. Coordination between national, EU, and global health bodies will also play a key role in ensuring steady vaccine and medication availability.
Read also:
- India's Agriculture Minister Reviews Sector Progress Amid Heavy Rains, Crop Areas Up
- Over 1.7M in Baden-Württemberg at Poverty Risk, Emmendingen's Housing Crisis Urgent
- Life Expectancy Soars, But Youth Suicide and Substance Abuse Pose Concern
- Cyprus, Kuwait Strengthen Strategic Partnership with Upcoming Ministerial Meeting
